Scarica l'app Stockscreener
7.35
0.82%
0.06
Dopo l'orario di chiusura:
7.33
-0.02
-0.27%
Precedente Chiudi:
$7.29
Aprire:
$7.31
Volume 24 ore:
9.55M
Relative Volume:
0.69
Capitalizzazione di mercato:
$2.73B
Reddito:
$3.49M
Utile/perdita netta:
$-663.48M
Rapporto P/E:
-3.2832
EPS:
-2.2387
Flusso di cassa netto:
$-115.08M
1 W Prestazione:
+0.14%
1M Prestazione:
+1.38%
6M Prestazione:
+77.54%
1 anno Prestazione:
+55.72%
Intervallo 1D:
$7.30
$7.37
Intervallo di 1 settimana:
$7.23
$7.41
Portata 52W:
$3.265
$7.45
Ataibeckley Inc Stock (ATAI) Company Profile
Nome
Ataibeckley Inc
Settore
Industria
Telefono
1 929 207 2670
Indirizzo
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.35 | 2.70B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Deutsche Bank | Buy |
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-07-29 | Iniziato | Oppenheimer | Outperform |
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Ataibeckley Inc Borsa (ATAI) Ultime notizie
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report? - Yahoo Finance
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too? - Stocktwits
Why Is ATAI Stock Soaring 59% After-Hours? - Stocktwits
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from S&P TMI Index - marketscreener.com
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from S&P Global BMI Index - marketscreener.com
Shareholders clear Lilly merger for AtaiBeckley (ATAI), with closing still subject to conditions - Stock Titan
ATAI: Merger agreement with Eli Lilly and Company received shareholder approval - TradingView
ATAI: Merger agreement with Eli Lilly and Company approved by shareholders; all proposals passed - TradingView
AtaiBeckley Inc.(NasdaqGM: ATAI) dropped from Russell 2000 Value Benchmark - marketscreener.com
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Atai Beckley (NASDAQ:ATAI) Clears Minervini Trend Template and High-Growth Momentum Screen - ChartMill
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates A - The National Law Review
Jim Cramer Isn't Sure If There’s Upside In This Health Care Stock - Benzinga
AtaiBeckley merger with Eli Lilly clears HSR waiting period; UK, Australia reviews progressing - TradingView
Ataibeckley Hart-Scott-Rodino Waiting Period For Eli Lilly Merger Expired August 28 - TradingView
Lilly–AtaiBeckley (NASDAQ: ATAI) merger clears hurdles, not the finish line - Stock Titan
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc.ATAI - Sahm
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates - GuruFocus
Eli Lilly-AtaiBeckley deal approved in Australia - MLex
ATAI Beckley earnings up next in final report before acquisition - Investing.com
How Investors Are Reacting To AtaiBeckley (ATAI) Rising Revenue But Deepening Net Losses - simplywall.st
AtaiBeckley (ATAI) Price: Ends Up by 0.96% at $7.36 at the Close; Levels: Support at $6.99 and Resistance at $7.73 Frame the Range for the Current SessionHot Stock Picks - Vinanet
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? - TradingView
AtaiBeckley(ATAI) Stock Options Chain | Quotes & News - Moomoo
Oppenheimer Downgrades AtaiBeckley to Market Perform From Outperform - marketscreener.com
Oppenheimer Downgrades AtaiBeckley(ATAI.US) to Hold Rating - Moomoo
Biotech Stocks At 52-Week HighsETON +44%, DXCM, ORKA, CON, ATAI - RTTNews
AtaiBeckley (ATAI) Q1 2026 Earnings: 23% EPS Beat Offsets Pre-Revenue ProfileCash Flow Report - Vinanet
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 28%EPS Growth Report - Vinanet
ATAI Beckley earnings beat by $0.03, revenue topped estimates - Investing.com South Africa
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates by 23% as Shares Surge 28%Analyst Coverage Count - Vinanet
Atai stock hits 52-week high of $7.26 - Investing.com
ATAI Q1 2026 Earnings: Narrower-than-Expected Loss Drives 28% Stock Move Amid Pre-Revenue StatusEarnings Expansion Phase - Vinanet
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Atai Beckley (NASDAQ:ATAI): What Does the Latest Update Mean for Trial Progress? - Kalkine Media
ATAI Q1 2026 Earnings: Narrower-Than-Expected Loss of -$0.08 Beats Estimates Despite No RevenueHigh Growth Earnings - Vinanet
Deutsche Bank Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $8 - Moomoo
Deutsche Bank Downgrades AtaiBeckley to Hold From Buy, Adjusts PT to $8 From $12 - marketscreener.com
ATAI Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 21% Share SurgeEarnings Cycle Report - Vinanet
AtaiBeckley Inc. Stock 12‑Month Price Target Cut to $8.83, Implies 22% Upside - TradingView
ATAI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
AtaiBeckley Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AtaiBeckley (NASDAQ: ATAI) to be acquired by Eli Lilly in $6.75 cash deal plus CVR - Stock Titan
AtaiBeckley Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com - Investing.com UK
Eli Lilly, AtaiBeckley filed US premerger forms July 29, got German approval July 30 - MLex
AtaiBeckley (NASDAQ: ATAI) backs $6.75 cash sale to Lilly plus CVR upside - Stock Titan
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know - Yahoo Finance
AtaiBeckley Inc. (ATAI): Investor Outlook with a 33.53% Potential Upside Amid Clinical Innovations - DirectorsTalk Interviews
Ataibeckley Inc Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):